Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2021-05-06 Board/Management Inform…
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 6, 2021, for Collegium Pharmaceutical, Inc. It reports two main items: Item 2.02 (Results of Operations and Financial Condition) which references a press release announcing quarterly financial results for the period ended March 31, 2021, and Item 5.02 (Departure and Appointment of Officers) detailing the resignation of the CFO and appointment of a new CFO. The document includes the full text of the press release as an exhibit but does not itself contain detailed financial statements or substantive financial data. The primary content is a current report on significant corporate events, including management changes and a financial results announcement. This fits the category of a current report on management changes and operational updates rather than a full quarterly or annual report. Therefore, the best classification is 'MANG' (Board/Management Information) because of the detailed announcement of changes in senior management, combined with financial results announcement which is typical in 8-K filings. Confidence is high given the clear presence of management change details and the nature of the filing as a Form 8-K.
2021-05-06 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about the annual meeting date, proposals to be voted on, board recommendations, and instructions for voting. It does not contain the full proxy statement itself but rather additional materials or a notice regarding proxy materials availability. The document is not the full Annual Report, nor is it an earnings release or other financial report. It is specifically related to proxy solicitation and shareholder voting information. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length (6343 characters) and content confirm it is not merely a brief announcement but detailed proxy materials, supporting a high confidence score.
2021-04-07 English
DEF 14A
Proxy Solicitation & Information Statement
2021-04-07 English
PRIMARY DOCUMENT
Director's Dealing
2021-04-06 English
PRIMARY DOCUMENT
Director's Dealing
2021-04-06 English
PRIMARY DOCUMENT
Director's Dealing
2021-04-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.